Liquid Biopsy Study Presented at ASCO Uncovers Somatic Mutations Consistent With Tissue-Based Tests | GenomeWeb

CHICAGO (GenomeWeb) – Blood-based liquid biopsies can uncover somatic mutation patterns and distributions similar to those found by directly testing tumor tissue samples, according to research presented at the American Society of Clinical Oncology meeting here this weekend.

Researchers from the University of California, liquid biopsy technology firm Guardant Health, and Vista Oncology examined somatic mutation patterns gleaned from liquid biopsies for more than 15,000 advanced cases, representing more than 50 cancer types, using Guardant Health's Guardant360 test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

Sponsored by
Agilent Technologies

This webinar will discuss a genomic strategy that detects single nucleotide variants and copy number variants in a single assay.

Sponsored by

This webinar will be an interactive roundtable discussion on established and emerging regulatory, scientific, and medical topics related to next-generation sequencing in the clinical setting.